The Company has a diverse product pipeline that includes marketed products with superior therapeutic indices and drug candidates with enhanced molecular structures. Dexanabinol has entered a phase III trial in Europe, with the U.S. arm of the trial expected to start later in 2001. PARS portfolio of drugs targets diseases of the eye and the Central Nervous System. Revenues reflect market share gains.
Higher loss reflects increased staffing levels and activity in the cannabinoid program.
All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Event data provided by StreetEvents . Data and information is provided for informational purposes only, and is not intended for trading purposes.